BPR1K871
BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor with IC50s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy[1].
Product Specifications
CAS Number
2443767-35-7
Product Name Alternative
DBPR114
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
FLT3
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bpr1k871.html
Purity
99.12
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC(Cl)=CC=C1)NC2=NC=C(S2)CCNC3=NC=NC4=C3C=CC(OCCCN(C)C)=C4
Molecular Formula
C25H28ClN7O2S
Molecular Weight
526.05
Precautions
H302, H315, H319, H335
References & Citations
[1]Hsu YC, et al. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation. 2016 Dec 27; 7 (52) : 86239–86256.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K0041204 1.0 µg DNA
ADAM3B sgRNA CRISPR Lentivector (Human) (Target 3)
Sign In for Pricing
View Details 
bs-16524R-BF594 100 µL
ZNF674 Polyclonal Antibody, AbBy Fluor™ 594 Conjugated
Sign In for Pricing
View Details 
orb1445402 500 µg
Natriuretic Peptide Receptor A Antibody Blocking peptide
Sign In for Pricing
View Details